Dean R Artis

Summary

Publications

  1. pmc Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
    Dean R Artis
    Plexxikon Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    Proc Natl Acad Sci U S A 106:262-7. 2009
  2. pmc Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
    Chao Zhang
    Plexxikon Inc, Berkeley, CA 94710
    Proc Natl Acad Sci U S A 110:5689-94. 2013
  3. pmc Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    Gideon Bollag
    Plexxikon Inc, 91 Bolivar Drive, Berkeley, California 94710, USA
    Nature 467:596-9. 2010
  4. pmc Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
    James Tsai
    Plexxikon, Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    Proc Natl Acad Sci U S A 105:3041-6. 2008
  5. ncbi request reprint Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma
    Abhinav Kumar
    Plexxikon, Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    J Mol Biol 348:183-93. 2005
  6. ncbi request reprint A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design
    Graeme L Card
    Plexxikon Inc, 91 Bolivar Dr, Berkeley, California 94710, USA
    Nat Biotechnol 23:201-7. 2005

Collaborators

Detail Information

Publications6

  1. pmc Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent
    Dean R Artis
    Plexxikon Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    Proc Natl Acad Sci U S A 106:262-7. 2009
    ..Indeglitazar has now progressed to Phase II clinical evaluations for Type 2 diabetes mellitus (T2DM)...
  2. pmc Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
    Chao Zhang
    Plexxikon Inc, Berkeley, CA 94710
    Proc Natl Acad Sci U S A 110:5689-94. 2013
    ..More importantly, the dual FMS and KIT inhibition profile has translated into a combination of benefits in preclinical disease models of inflammation and cancer...
  3. pmc Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    Gideon Bollag
    Plexxikon Inc, 91 Bolivar Drive, Berkeley, California 94710, USA
    Nature 467:596-9. 2010
    ..These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity...
  4. pmc Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
    James Tsai
    Plexxikon, Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    Proc Natl Acad Sci U S A 105:3041-6. 2008
    ....
  5. ncbi request reprint Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma
    Abhinav Kumar
    Plexxikon, Inc, 91 Bolivar Drive, Berkeley, CA 94710, USA
    J Mol Biol 348:183-93. 2005
    ..Based on the structural information, opportunities for optimization of one specific example are discussed...
  6. ncbi request reprint A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design
    Graeme L Card
    Plexxikon Inc, 91 Bolivar Dr, Berkeley, California 94710, USA
    Nat Biotechnol 23:201-7. 2005
    ....